Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

3768 - Gene mutational analyses in 154 ovarian cancer (OC) samples from the ROSiA study of front-line bevacizumab (BEV)-containing therapy for OC


09 Sep 2017


Poster display session


Regula Deurloo


Annals of Oncology (2017) 28 (suppl_5): v330-v354. 10.1093/annonc/mdx372


R. Deurloo1, N. Colombo2, C. Mendiola3, F. Selle4, J. Korach5, M.Z. Oestergaard1, M. Bylesjo6, H. Urban7, Y. Ghazi8, A. Oza9

Author affiliations

  • 1 Oncology Biomarker Development, F Hoffmann-La Roche Ltd, 4070 - Basel/CH
  • 2 Division Of Medical Gynecologic Oncology, European Institute of Oncology and University of Milano-Bicocca, Milan/IT
  • 3 Department Of Medical Oncology, University Hospital 12 de Octubre, Madrid/ES
  • 4 Medical Oncology Service, Groupe Hospitalier Diaconesses Croix Saint-Simon and Alliance Pour la Recherche en Cancérologie, Paris/FR
  • 5 Gynecologic Oncology Department, Sheba Medical Center, Tel Hashomer/IL
  • 6 Bioinformatics Department, Fios Genomics Ltd, Edinburgh/GB
  • 7 Product Development Medical Affairs Biometrics, F Hoffmann-La Roche Ltd, Basel/CH
  • 8 Global Product Development/medical Affairs, F Hoffmann-La Roche Ltd, Basel/CH
  • 9 Cancer Clinical Research Unit, Princess Margaret Cancer Centre, Toronto/CA


Abstract 3768


In the single-arm ROSiA study (NCT01239732), 1021 patients (pts) with newly diagnosed OC received 12–24 wks of carboplatin + paclitaxel with BEV for up to 24 mo or until progression [Oza 2016]. Progression-free survival (PFS) was a secondary endpoint.


In an optional translational research substudy, tumour tissue samples collected before BEV were analysed using Foundation Medicine Inc.’s FoundationOne® (FMOne) gene panel. Prevalence of gene alterations, tumour mutational burden (TMB) and potential prognostic effects were assessed in exploratory gene mutational analyses using Cox proportional hazards models. Correlations between TMB and BRCA1 mutation and immunohistochemical expression of the immune markers PD-L1 and CD8 were assessed.


The FMOne population (n = 154) was representative of the ITT population (n = 1021) for baseline characteristics but had slightly more favourable PFS (median 30.2 vs 25.5 mo, respectively; hazard ratio [HR] 1.16 [95% CI 0.92–1.45]; p = 0.21). The most common gene alterations (predominantly short variant) were TP53 (79% of pts), BRCA1 (22%), NF1 (14%), KRAS (10%), PIK3CA (9%) and BRCA2 (7%). MYC, TERC, GNAS and CCNE1 were amplified in 25%, 16%, 7% and 7%, respectively. The mean TMB (excluding germline polymorphisms and known cancer drivers) was 4.5/megabase (Mb; range 0–43). Only 2 pts had a TMB >15/Mb; 43 had a TMB ≥5/Mb. In univariate Cox regression analyses, none of the mutations explored showed a clear association with PFS. PFS slightly (not statistically significantly) favoured pts with (n = 34) vs without (n = 118) BRCA1 mutation (median 30.4 vs 28.1 mo, respectively; HR 0.76 [95% CI 0.44–1.31]; p = 0.32). TMB and PFS showed no association. No meaningful correlations were seen between either TMB or BRCA1 mutation and expression of the immune markers PD-L1 and CD8 on immune cells.


Samples from pts with newly diagnosed OC indicated relatively infrequent gene alterations and low TMB. None of the gene alterations evaluated suggested prognostic value, but low frequency of these mutations and the relatively small number of samples in ROSiA limit interpretation, particularly for the correlation analyses.

Clinical trial identification


Legal entity responsible for the study

F Hoffmann-La Roche Ltd


F Hoffmann-La Roche Ltd


R. Deurloo, Y. Ghazi: Employee, shares: F Hoffmann-La Roche. N. Colombo: Travel expenses from Roche for ROSiA steering committee meetings, personal fees from AstraZeneca and PharmaMar for advisory boards and speaker engagements, and personal fees from Clovis, Amgen, MSD, and Pfizer for advisory boards. C. Mendiola: Non-financial support from Roche Farma Spain and AstraZeneca Spain. F. Selle: Honoraria for consultant/advisory role: Roche; travel/accommodation expenses: Roche, AstraZeneca. M.Z. Oestergaard, H-J. Urban: Employee: F Hoffmann-La Roche. M. Bylesjo: Employee of Fios Genomics Ltd, a contract research organisation contracted to provide statistical services to F Hoffmann-La Roche Ltd. A. Oza: Travel expenses from Roche for advisory boards and ROSiA steering committee meetings. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.